IS8129A - Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða - Google Patents
Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíðaInfo
- Publication number
- IS8129A IS8129A IS8129A IS8129A IS8129A IS 8129 A IS8129 A IS 8129A IS 8129 A IS8129 A IS 8129A IS 8129 A IS8129 A IS 8129A IS 8129 A IS8129 A IS 8129A
- Authority
- IS
- Iceland
- Prior art keywords
- phenyl
- methylamide
- paroxetine
- piperazin
- anxiety
- Prior art date
Links
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 title 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960002296 paroxetine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308968.7A GB0308968D0 (en) | 2003-04-17 | 2003-04-17 | Medicaments |
| PCT/EP2004/004122 WO2004091616A1 (en) | 2003-04-17 | 2004-04-16 | Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8129A true IS8129A (is) | 2005-11-15 |
Family
ID=9956996
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8129A IS8129A (is) | 2003-04-17 | 2005-11-15 | Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða |
| IS8128A IS8128A (is) | 2003-04-17 | 2005-11-15 | Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8128A IS8128A (is) | 2003-04-17 | 2005-11-15 | Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20060217395A1 (is) |
| EP (4) | EP1615642A1 (is) |
| JP (4) | JP2006523650A (is) |
| KR (2) | KR20060003876A (is) |
| CN (2) | CN1809359A (is) |
| AU (2) | AU2004229179A1 (is) |
| BR (2) | BRPI0409379A (is) |
| CA (2) | CA2522311A1 (is) |
| CO (1) | CO5700753A2 (is) |
| GB (1) | GB0308968D0 (is) |
| IS (2) | IS8129A (is) |
| MA (2) | MA27730A1 (is) |
| MX (2) | MXPA05011063A (is) |
| NO (2) | NO20055367L (is) |
| PL (2) | PL377857A1 (is) |
| RU (2) | RU2005135649A (is) |
| WO (4) | WO2004091616A1 (is) |
| ZA (2) | ZA200508067B (is) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0403149D0 (en) * | 2004-02-12 | 2004-03-17 | Glaxo Group Ltd | Medicament |
| GB0409098D0 (en) * | 2004-04-23 | 2004-05-26 | Glaxo Group Ltd | Medicament |
| GB0426942D0 (en) * | 2004-12-08 | 2005-01-12 | Glaxo Group Ltd | Medicament |
| WO2007012968A2 (en) * | 2005-07-29 | 2007-02-01 | Aurobindo Pharma Ltd | Stable dosage form of an antidepressant |
| GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| WO2012175434A1 (en) * | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Pharmaceutical formulations comprising vestipitant |
| CN103446066B (zh) * | 2013-09-16 | 2014-12-24 | 南通丝乡丝绸有限公司 | 帕罗西汀冻干粉针及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | Piperidine derivatives their preparation and pharmaceutical compositions containing them |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| CA2287397A1 (en) * | 1997-04-24 | 1998-10-29 | Merck Sharp & Dohme Limited | Use of an nk-1 receptor antagonist and an ssri for treating obesity |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| US6436928B1 (en) * | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
| CN1434805A (zh) * | 1999-12-17 | 2003-08-06 | 先灵公司 | 选择性神经激肽拮抗剂 |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| GB0119797D0 (en) * | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
| MXPA04004477A (es) * | 2001-11-13 | 2004-08-11 | Schering Corp | Antagonistas del neuropeptido neuroquinina-1(nk1). |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
-
2003
- 2003-04-17 GB GBGB0308968.7A patent/GB0308968D0/en not_active Ceased
-
2004
- 2004-04-16 WO PCT/EP2004/004122 patent/WO2004091616A1/en not_active Ceased
- 2004-04-16 KR KR1020057019521A patent/KR20060003876A/ko not_active Withdrawn
- 2004-04-16 MX MXPA05011063A patent/MXPA05011063A/es unknown
- 2004-04-16 EP EP04739086A patent/EP1615642A1/en not_active Withdrawn
- 2004-04-16 PL PL377857A patent/PL377857A1/pl not_active Application Discontinuation
- 2004-04-16 WO PCT/EP2004/004126 patent/WO2004091624A1/en not_active Ceased
- 2004-04-16 RU RU2005135649/15A patent/RU2005135649A/ru not_active Application Discontinuation
- 2004-04-16 CN CNA2004800172252A patent/CN1809359A/zh active Pending
- 2004-04-16 AU AU2004229179A patent/AU2004229179A1/en not_active Abandoned
- 2004-04-16 CA CA002522311A patent/CA2522311A1/en not_active Abandoned
- 2004-04-16 BR BRPI0409379-8A patent/BRPI0409379A/pt not_active Application Discontinuation
- 2004-04-16 EP EP04727896A patent/EP1653956A1/en not_active Withdrawn
- 2004-04-16 US US10/552,871 patent/US20060217395A1/en not_active Abandoned
- 2004-04-16 CA CA002522313A patent/CA2522313A1/en not_active Abandoned
- 2004-04-16 US US10/552,982 patent/US20060287325A1/en not_active Abandoned
- 2004-04-16 KR KR1020057019520A patent/KR20060003875A/ko not_active Withdrawn
- 2004-04-16 WO PCT/EP2004/004121 patent/WO2004091615A1/en not_active Ceased
- 2004-04-16 US US10/552,870 patent/US20060241143A1/en not_active Abandoned
- 2004-04-16 US US10/552,869 patent/US20060241124A1/en not_active Abandoned
- 2004-04-16 BR BRPI0409377-1A patent/BRPI0409377A/pt not_active Application Discontinuation
- 2004-04-16 JP JP2006505186A patent/JP2006523650A/ja active Pending
- 2004-04-16 PL PL377858A patent/PL377858A1/pl not_active Application Discontinuation
- 2004-04-16 EP EP04739085A patent/EP1615641A1/en not_active Withdrawn
- 2004-04-16 JP JP2006505185A patent/JP2006523649A/ja active Pending
- 2004-04-16 WO PCT/EP2004/004124 patent/WO2004091617A1/en not_active Ceased
- 2004-04-16 EP EP04727895A patent/EP1613325A1/en not_active Withdrawn
- 2004-04-16 RU RU2005135647/15A patent/RU2005135647A/ru not_active Application Discontinuation
- 2004-04-16 JP JP2006505187A patent/JP2006523651A/ja active Pending
- 2004-04-16 AU AU2004229181A patent/AU2004229181A1/en not_active Abandoned
- 2004-04-16 JP JP2006505188A patent/JP2006523652A/ja active Pending
- 2004-04-16 MX MXPA05011064A patent/MXPA05011064A/es unknown
- 2004-04-16 CN CNA2004800171620A patent/CN1809355A/zh active Pending
-
2005
- 2005-10-06 ZA ZA200508067A patent/ZA200508067B/en unknown
- 2005-10-06 ZA ZA200508068A patent/ZA200508068B/en unknown
- 2005-10-14 CO CO05105292A patent/CO5700753A2/es not_active Application Discontinuation
- 2005-10-19 MA MA28561A patent/MA27730A1/fr unknown
- 2005-10-19 MA MA28562A patent/MA27731A1/fr unknown
- 2005-11-14 NO NO20055367A patent/NO20055367L/no not_active Application Discontinuation
- 2005-11-14 NO NO20055368A patent/NO20055368L/no not_active Application Discontinuation
- 2005-11-15 IS IS8129A patent/IS8129A/is unknown
- 2005-11-15 IS IS8128A patent/IS8128A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120252A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| MX2010006238A (es) | Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico. | |
| WO2004046120A3 (en) | Diaminotriazoles useful as inhibitors of protein kinases | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer | |
| UA100364C2 (xx) | Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів | |
| DK3889142T3 (da) | 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| IL183526A0 (en) | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino)benzamides as cdk inhibitors | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
| DE60329330D1 (de) | Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors | |
| EP1786428A4 (en) | PDE5 INHIBITOR COMPOSITIONS AND METHOD FOR TREATING DISEASE | |
| IS8129A (is) | Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða | |
| DE602005009255D1 (de) | Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit | |
| NO20085052L (no) | 4-((fluorofenoksyl)fenylmetyl)piperidin metansulfonat: anvendelser, synteseprosess og farmasoytiske sammensetninger | |
| ATE471315T1 (de) | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
| DE60322110D1 (de) | Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten | |
| FR2862968B1 (fr) | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique | |
| ZA200705073B (en) | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as CDK inhibitors |